-Centers for Disease Control and Prevention. 2019 Viral Hepatitis Surveillance Report. Published July 2021.
NASTAD’s Hepatitis team provides guidance and technical assistance to strengthen the capacity of state and local health departments to develop, maintain and enhance comprehensive hepatitis programs as they address the continuum from prevention through cure.
Hepatitis is our jumping-off point to address larger issues. Hepatitis is the doorway to immigrant justice, LGBTQIA+ rights, houselessness, abolition, and social justice work.
In 2019, NASTAD launched the Hepatitis Technical Assistance Center (HepTAC). HepTAC is an online technical assistance (TA) and capacity-building center for health department hepatitis programs. The primary goal of HepTAC is to build state and local technical expertise and enhance health department capacity to eliminate viral hepatitis.
Additionally, in collaboration between NASTAD and CDC, oversees the VLC, which is a virtual learning community and training series designed to support viral hepatitis health department staff implement the viral hepatitis prevention and surveillance activities set forth in CDC’s Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments (CDC-RFA-PS21-2103) and is open to all state, territorial, and local health departments.
NASTAD in partnership with National Viral Hepatitis Roundtable (NVHR) and National Association of County and City Health Officials (NACCHO) are implementing and facilitating the Hepatitis Network for Education and Testing (HepNET), a network of state, local and tribal health departments (LHDs/THDs), community-based organizations (CBOs), tribal organizations, clinical providers, people with lived experience, syringe services programs (SSPs) and harm reduction programs focused on identifying and addressing the unmet needs of people who inject drugs (PWID). NASTAD and its partners will provide technical assistance and training to network members with a focus on hepatitis B and hepatitis C for people who inject drugs to improve their access to viral hepatitis education, prevention, testing, linkage to care, and treatment.